Atopic Dermatitis

Doxepin Hydrochloride (Standard) is the analytical standard of Doxepin Hydrochloride (HY-B0725). This product is intended for research and analytical applications. Doxepin Hydrochloride is an orally active, blood-brain barrier penetrant tricyclic antidepressant with multiple activities including hypnosis, sedation, analgesia and vasodilation. Doxepin Hydrochloride enhances the expression of PSD-95 and synapsin 1 via the PI3K/AKT/mTOR signaling pathway, and is metabolized to DesmethylDoxepin Hydrochloride in vivo. Doxepin Hydrochloride can be used in research related to various diseases such as depression, anxiety, obesity and atopic dermatitis.

Solaprubart (STAR-0310) is a fully human IgG1 subtype monoclonal antibody targeting OX40 (CD134/TNFRSF4), with a K_d of 7.2 nM. By blocking the OX40/OX40L co-stimulatory signal, Solaprubart effectively inhibits cytokine release (IFN-γ, TNF-α, IL-5, IL-13) from activated effector T cells (Th1/Th2/Th17-associated). Solaprubart can be used in research related to moderate-to-severe atopic dermatitis.

Olevaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4, which can be used for the research of autoimmune diseases such as atopic dermatitis and alopecia areata.

HY-072808 is a cyclic nucleotide phosphodiesterase-4B (PDE4B) inhibitor.HY-072808 modulates cyclic nucleotide signaling via selective inhibition of the PDE4B subtype.HY-072808 can be used for the research of atopic dermatitis.

Doxepin-d₃ hydrochloride is the deuterated-labeled Doxepin Hydrochloride (HY-B0725). Doxepin Hydrochloride is an orally active, blood-brain barrier penetrant tricyclic antidepressant with multiple activities including hypnosis, sedation, analgesia and vasodilation. Doxepin Hydrochloride enhances the expression of PSD-95 and synapsin 1 via the PI3K/AKT/mTOR signaling pathway, and is metabolized to DesmethylDoxepin Hydrochloride in vivo. Doxepin Hydrochloride can be used in research related to various diseases such as depression, anxiety, obesity and atopic dermatitis.

TAVO101 is a humanized anti-TSLP antibody with an EC₅₀ of 0.19 nM against hTSLP. TAVO101 inhibits STAT5 activation and CCL17 release. TAVO101 carries Fc region mutations that enhance its binding to FcRn while reducing its binding to FcγRI, FcγRIIIA and C1q, thereby attenuating effector functions. TAVO101 reduces the levels of inflammatory markers, cell infiltration and histopathological damage in preclinical models of asthma, psoriasis and atopic dermatitis. TAVO101 can be used for research related to asthma, psoriasis and atopic dermatitis.

Pyrrolidone carboxylic acid (PCA) is one of the main components (accounting for approximately 12%) of natural moisturizing factors (NMF) in the mammalian epidermal stratum corneum, and it is produced by the degradation of filaggrin. It exhibits multiple biological activities such as skin moisturization, central GABA release, anxiolysis, and auxiliary ethanol metabolism. The content of Pyrrolidone carboxylic acid correlates with the clinical severity of atopic dermatitis lesions, skin barrier function, and inflammation levels, and shows a negative correlation with the expression of TNF-α and IL-13. Pyrrolidone carboxylic acid can serve as a key skin biomarker for skin barrier function and health.

Methylchloroisothiazolinone is a widely used fungicide and also an aquatic pollutant with pro-inflammatory activity and neurotoxicity. Methylchloroisothiazolinone induces the production of pro-inflammatory cytokines (such as IL-1β, TNF-α, IL-6) by activating the NF-κB signaling pathway and upregulating TLR4 expression, thereby triggering allergic contact dermatitis. Methylchloroisothiazolinone reduces cholinesterase activity and exacerbates oxidative stress by impairing catalase activity and disrupting redox balance. Methylchloroisothiazolinone poses significant harm to Mediterranean mussels, reducing the viability of hemocytes and digestive gland cells, inhibiting immune phagocytic function, and disrupting osmoregulatory capacity. Methylchloroisothiazolinone is used in studies on allergic contact dermatitis and related immunotoxicity mechanisms.

HB-0043 is a IL-17A and IL-36R antagonist. HB-0043 blocks IL-17A- and IL-36R-mediated signaling pathways, inhibits the production of inflammatory cytokines, and reduces the secretion of pro-inflammatory cytokines IL-6 and IL-8. HB-0043 alleviates skin thickening and inflammatory responses in oxazolone-induced and Imiquimod (HY-B0180)-induced skin reaction mouse models. HB-0043 is applicable for the research of atopic dermatitis and psoriasis.

Vibozilimod (SCD-044) is an oral S1P1/EDG1 receptor-selective agonist with an EC₅₀ of <1 nM. Vibozilimod promotes S1P1/EDG1 receptor internalization, inhibits lymphocyte migration, induces lymphopenia and reduces lymphocyte counts. Vibozilimod is used for the research of inflammatory diseases such as psoriasis and atopic dermatitis.

Doxepin-d₃ is the deuterated-labeled Doxepin (HY-B0725A). Doxepin is an orally active, blood-brain barrier penetrant tricyclic antidepressant with multiple activities including hypnosis, sedation, analgesia and vasodilation. Doxepin enhances the expression of PSD-95 and synapsin 1 via the PI3K/AKT/mTOR signaling pathway, and is metabolized to Desmethyldoxepin in vivo. Doxepin can be used in research related to various diseases such as depression, anxiety, obesity and atopic dermatitis.

Keap1-Nrf2 PPI-IN-2 is a Keap1-Nrf2 PPI inhibitor with an EC₅₀ of 14.2 μM. Keap1-Nrf2 PPI-IN-2 covalently binds to Keap1 cysteine residues through its electrophilic itaconate moiety, disrupts the Keap1-Nrf2 protein-protein interaction, releases Nrf2, and promotes its nuclear translocation and antioxidant gene expression, thereby reducing ROS and inhibiting IL-13 production. Keap1-Nrf2 PPI-IN-2 can be used for research on atopic dermatitis.

Fepradinol is an orally active nonsteroidal anti-inflammatory agent. Fepradinol inhibits the increase in vascular permeability induced by histamine, 5-hydroxytryptamine, and bradykinin, reduces exudate volume, prevents leukocyte migration, and suppresses acute inflammation models. Fepradinol also induces thrombotic vasculopathy with epidermal necrosis, without leukocytoclastic vasculitis; triggers occlusive contact dermatitis presenting as purpuric papulonecrotic lesions, and causes strongly positive patch test reactions. Fepradinol can be used in research related to occlusive contact dermatitis and acute inflammation.

C18:0-d₇ GD1b Ceramide (d18:1/18:0-d7) is the deuterated-labeled C18:0 GD1b Ceramide (d18:1/18:0), synthetic (HY-167597). C18:0 GD1b Ceramide (d18:1/18:0), synthetic is a synthetic ganglioside. C18:0 GD1b Ceramide (d18:1/18:0), synthetic is a Ganglioside GD1b derivative and a high-purity research standard. C18:0 GD1b Ceramide (d18:1/18:0), synthetic can be used for research on atopic dermatitis and Alzheimer's disease.

Centella asiatica extract is an orally active herbal extract. Centella asiatica extract scavenges free radicals, increases stratum corneum hydration, improves epidermal barrier function, and reduces skin redness and skin pH. Centella asiatica extract inhibits pro-inflammatory cytokines, suppresses p38 MAPK phosphorylation, reduces mast cell infiltration, and decreases the expression of TNF-α, IL-4, IL-5, IL-6, IL-17, CXCL9, iNOS and COX-2. Centella asiatica extract upregulates the expression of BDNF and downregulates the expression of VGLUT1, and exhibits neuroprotective effects under hypoxic conditions. Centella asiatica extract inhibits pro-inflammatory M1 macrophage polarization and prevents adipose tissue senescence. Centella asiatica extract can be used in studies related to hypoxia-induced neurological dysfunction, atopic dermatitis, and obesity-induced insulin resistance.

Anti-inflammatory agent 121 is a protease inhibitor, with IC₅₀ values against different targets as follows: 1.3 μM (Staphylococcus aureus type I staphylokinase), 2.2 μM (Staphylococcus aureus type II staphylokinase), 2.3 μM (human MMP-1), 2.7 μM (human MMP-2), 1.4 μM (human MMP-8), 4.6 μM (human MMP-9), and 79 μM (human ADAM17). Anti-inflammatory agent 121 inhibits the activities of staphylococcal serine protease glutamyl endopeptidase (V8 protease) and cysteine protease staphylococcal protease B in Staphylococcus aureus cultures. Anti-inflammatory agent 121 inhibits protease activity in skin wash samples, metalloprotease (staphylokinase) activity in Staphylococcus aureus culture supernatants, and staphylokinase-mediated activation of pro-urokinase-type plasminogen activator (pro-uPA). Anti-inflammatory agent 121 can be used in the research of atopic dermatitis.

KLK5-IN-1 is a selective kallikrein 5 (KLK5) inhibitor with an IC₅₀ of 14 nM and a K_i of 11 nM. KLK5-IN-1 reduces KLK5-mediated PAR2-dependent calcium mobilization. KLK5-IN-1 improves epithelial barrier integrity. KLK5-IN-1 can be used in research related to atopic dermatitis and Netherton syndrome.

PDE4-IN-36 is a phosphodiesterase 4 (PDE4) inhibitor with significant inhibitory activity at 10 μM. PDE4-IN-36 can be used in the research of psoriasis and atopic dermatitis.

ANB032 is a human IgG4 kappa BTLA agonist monoclonal antibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines. ANB032 can be used for the research of atopic dermatitis[1].

XW-17 is a PARP14 inhibitor with an IC₅₀ of 3.03 nM and selectivity over other PARP family members.XW-17 suppresses PARP14-mediated mono-ADP-ribosylation, engages and stabilizes endogenous PARP14 protein.XW-17 attenuates skin lesions and decreases expression of IL-4, IL-13, IgE, and IL-17A in an atopic dermatitis-like mouse model.XW-17 can be used for the research of atopic dermatitis.